IL161676A0 - Pharmaceutical composition comprising an adenosine a1/a2 agonist and a sodium hydrogen exchanger inhibitor - Google Patents
Pharmaceutical composition comprising an adenosine a1/a2 agonist and a sodium hydrogen exchanger inhibitorInfo
- Publication number
- IL161676A0 IL161676A0 IL16167602A IL16167602A IL161676A0 IL 161676 A0 IL161676 A0 IL 161676A0 IL 16167602 A IL16167602 A IL 16167602A IL 16167602 A IL16167602 A IL 16167602A IL 161676 A0 IL161676 A0 IL 161676A0
- Authority
- IL
- Israel
- Prior art keywords
- adenosine
- agonist
- pharmaceutical composition
- sodium hydrogen
- hydrogen exchanger
- Prior art date
Links
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 title 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 title 1
- 102000052126 Sodium-Hydrogen Exchangers Human genes 0.000 title 1
- 108091006672 Sodium–hydrogen antiporter Proteins 0.000 title 1
- 229960005305 adenosine Drugs 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33631501P | 2001-11-02 | 2001-11-02 | |
| GB0203596A GB0203596D0 (en) | 2002-02-15 | 2002-02-15 | Pharmaceutical composition comprising of adenosine A1/A2 agonist and a sodium hydrogen exchanger inhibitor |
| PCT/US2002/035096 WO2003039528A1 (en) | 2001-11-02 | 2002-11-01 | Pharmaceutical composition comprising an adenosine a1/a2 agonist and a sodium hydrogen exchanger inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL161676A0 true IL161676A0 (en) | 2004-09-27 |
Family
ID=26246972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL16167602A IL161676A0 (en) | 2001-11-02 | 2002-11-01 | Pharmaceutical composition comprising an adenosine a1/a2 agonist and a sodium hydrogen exchanger inhibitor |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20040248928A1 (pl) |
| EP (1) | EP1443916A1 (pl) |
| JP (1) | JP2005511590A (pl) |
| KR (1) | KR20050042225A (pl) |
| CN (1) | CN1585634A (pl) |
| BR (1) | BR0213820A (pl) |
| CA (1) | CA2465364A1 (pl) |
| HR (1) | HRP20040385A2 (pl) |
| HU (1) | HUP0401853A2 (pl) |
| IL (1) | IL161676A0 (pl) |
| MA (1) | MA27073A1 (pl) |
| MX (1) | MXPA04003124A (pl) |
| NO (1) | NO20042142L (pl) |
| PL (1) | PL369074A1 (pl) |
| RU (1) | RU2004116686A (pl) |
| WO (1) | WO2003039528A1 (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| JP4664797B2 (ja) * | 2005-10-13 | 2011-04-06 | ジーイー・メディカル・システムズ・グローバル・テクノロジー・カンパニー・エルエルシー | Ｍｒｉ装置 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| YU46200A (sh) * | 1998-02-27 | 2003-02-28 | Pfizer Products Inc. | N-(supstituisani peto-članog di-ili triaza dinezasićenog prstena)karbonil/guanidin derivati za tretiranje ishemije |
| CO5180581A1 (es) * | 1999-09-30 | 2002-07-30 | Pfizer Prod Inc | Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia |
-
2002
- 2002-11-01 WO PCT/US2002/035096 patent/WO2003039528A1/en not_active Ceased
- 2002-11-01 RU RU2004116686/15A patent/RU2004116686A/ru not_active Application Discontinuation
- 2002-11-01 CN CNA028214226A patent/CN1585634A/zh active Pending
- 2002-11-01 BR BR0213820-4A patent/BR0213820A/pt not_active IP Right Cessation
- 2002-11-01 IL IL16167602A patent/IL161676A0/xx unknown
- 2002-11-01 CA CA002465364A patent/CA2465364A1/en not_active Abandoned
- 2002-11-01 HR HR20040385A patent/HRP20040385A2/xx not_active Application Discontinuation
- 2002-11-01 EP EP02786638A patent/EP1443916A1/en not_active Withdrawn
- 2002-11-01 HU HU0401853A patent/HUP0401853A2/hu unknown
- 2002-11-01 JP JP2003541819A patent/JP2005511590A/ja active Pending
- 2002-11-01 MX MXPA04003124A patent/MXPA04003124A/es not_active Application Discontinuation
- 2002-11-01 PL PL02369074A patent/PL369074A1/pl not_active Application Discontinuation
- 2002-11-01 KR KR1020047006625A patent/KR20050042225A/ko not_active Withdrawn
-
2004
- 2004-04-06 MA MA27610A patent/MA27073A1/fr unknown
- 2004-04-30 US US10/835,964 patent/US20040248928A1/en not_active Abandoned
- 2004-05-25 NO NO20042142A patent/NO20042142L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003039528A1 (en) | 2003-05-15 |
| RU2004116686A (ru) | 2005-03-27 |
| HRP20040385A2 (en) | 2005-06-30 |
| NO20042142L (no) | 2004-05-25 |
| US20040248928A1 (en) | 2004-12-09 |
| CA2465364A1 (en) | 2003-05-15 |
| KR20050042225A (ko) | 2005-05-06 |
| MA27073A1 (fr) | 2004-12-20 |
| MXPA04003124A (es) | 2004-11-29 |
| CN1585634A (zh) | 2005-02-23 |
| BR0213820A (pt) | 2004-08-31 |
| HUP0401853A2 (hu) | 2004-12-28 |
| EP1443916A1 (en) | 2004-08-11 |
| JP2005511590A (ja) | 2005-04-28 |
| PL369074A1 (pl) | 2005-04-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2001284564A1 (en) | Nucleoside metabolism inhibitors | |
| PT1461039E (pt) | Composições farmacêuticas compreendendo cilostazol e um inibidor da captação de adenosina | |
| IL157741A0 (en) | Pharmaceutical compositions containing an antihyperplastic active agent | |
| GB0115320D0 (en) | Matrix | |
| HUP0303325A3 (en) | Pharmaceutical salts and pharmaceutical compositions containing them | |
| AU3831901A (en) | Matrix metalloproteinase inhibitors | |
| EP1466255A4 (en) | SUPER CHARGE MESSAGING DEVICE | |
| AU2210702A (en) | Gas exchange | |
| HUP0400328A3 (en) | Metalloproteinase inhibitor azoles and pharmaceutical compositions containing them | |
| HUP0302555A3 (en) | Pharmaceutical compositions containing gaba agonists and aldose reductase inhibitors | |
| EG24194A (en) | 5ht-a-partial agonist pharmaceutical compositions | |
| AU2001262242A1 (en) | Antistatic agent | |
| AU2002356284A8 (en) | Fast path message transfer agent | |
| HUP0303533A3 (en) | Adenosine a1 agonist adenosine derivatives | |
| PL342763A1 (en) | Matrix metaloprotease inhibitor | |
| EP1427040A4 (en) | GELING AGENT FOR AN ALKALINE CELL AND ALKALINE CELL | |
| PL369074A1 (pl) | Kompozycja farmaceutyczna zawierająca agonistę adenozyny A1/A2 i inhibitor wymiany jonów sodowych zwodorowymi | |
| HUP0302904A3 (en) | Matrix metalloproteinase inhibitors | |
| GB0203596D0 (en) | Pharmaceutical composition comprising of adenosine A1/A2 agonist and a sodium hydrogen exchanger inhibitor | |
| IL155055A0 (en) | Triazole derivatives and pharmaceutical compositions comprising them | |
| IL160734A0 (en) | Pharmaceutical composition comprising gamma-butyrobetaine | |
| PL351865A1 (en) | Application of a combination of the 1(nhe-1) type sodium-hydrogen exchanger inhibitor and some other compound in production of a drugs as well as pharmacological agent and set | |
| PL355453A1 (pl) | Środek farmaceutyczny | |
| PL368613A1 (pl) | Kompozycja farmaceutyczna zawierająca antagonistęLTB4 | |
| GB0122162D0 (en) | Agent |